Year |
Citation |
Score |
Low-probability matches (unlikely to be authored by this person) |
2021 |
Barrientos JC, Hillmen P, Salles G, Sharman J, Stilgenbauer S, Gurtovaya O, Xing G, Ruzicka B, Bhargava P, Ghia P, Pagel JM. No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Leukemia & Lymphoma. 62: 837-845. PMID 33297794 DOI: 10.1080/10428194.2020.1845339 |
0.043 |
|
2022 |
Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, Jiang W, Downie B, Mathur A, Mozaffarian A, Mozaffarian N, Gottenberg JE. Safety and Efficacy of Filgotinib, Lanraplenib, and Tirabrutinib in Sjögren's Syndrome: Randomised, Phase 2, Double-Blind, Placebo-Controlled Study. Rheumatology (Oxford, England). PMID 35377447 DOI: 10.1093/rheumatology/keac167 |
0.043 |
|
2021 |
Werth VP, Fleischmann R, Robern M, Touma Z, Tiamiyu I, Gurtovaya O, Pechonkina A, Mozaffarian A, Downie B, Matzkies F, Wallace D. Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study. Rheumatology (Oxford, England). PMID 34498056 DOI: 10.1093/rheumatology/keab685 |
0.04 |
|
2020 |
Baker M, Chaichian Y, Genovese M, Derebail V, Rao P, Chatham W, Bubb M, Lim S, Hajian H, Gurtovaya O, Patel U, Tumlin J. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. Rmd Open. 6. PMID 33380521 DOI: 10.1136/rmdopen-2020-001490 |
0.034 |
|
2011 |
Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry. 72: 1413-22. PMID 21672493 DOI: 10.4088/JCP.09m05934 |
0.032 |
|
2020 |
Keating CL, Zuckerman JB, Singh PK, McKevitt M, Gurtovaya O, Bresnik M, Marshall BC, Saiman L. Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation. Antimicrobial Agents and Chemotherapy. PMID 33318007 DOI: 10.1128/AAC.02327-20 |
0.03 |
|
2023 |
Gilchrist FJ, Bui S, Gartner S, McColley SA, Tiddens H, Ruiz G, Stehling F, Alani M, Gurtovaya O, Bresnik M, Watkins TR, Frankovic B, Skov M. ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 37455237 DOI: 10.1016/j.jcf.2023.06.008 |
0.029 |
|
2004 |
Isaev D, Solt K, Gurtovaya O, Reeves JP, Shirokov R. Modulation of the voltage sensor of L-type Ca2+ channels by intracellular Ca2+. The Journal of General Physiology. 123: 555-71. PMID 15111645 DOI: 10.1085/jgp.200308876 |
0.028 |
|
Hide low-probability matches. |